The outcomes of operations for 539 patients with Ebstein anomaly

Morgan L Brown1, Joseph A Dearani, Gordon K Danielson

  • 1Division of Cardiovascular Surgery, Mayo Clinic College of Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA.

Insights

This study reviewed long-term outcomes for Ebstein anomaly patients undergoing cardiac surgery. Surgical treatment offers low perioperative mortality and good long-term survival for Ebstein anomaly (EA).

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Congenital Heart Disease

Background:

  • Ebstein anomaly (EA) is a rare congenital heart defect affecting the tricuspid valve.
  • Surgical intervention is often necessary for symptomatic EA patients.
  • Understanding long-term outcomes is crucial for patient management.

Purpose of the Study:

  • To evaluate the long-term outcomes of patients with Ebstein anomaly who underwent cardiac surgery.
  • To identify factors associated with mortality and survival after surgery for EA.

Main Methods:

  • Retrospective review of patient records for Ebstein anomaly patients undergoing cardiac surgery.
  • Exclusion of patients with specific complex congenital heart conditions.
  • Data collection on perioperative and long-term outcomes, including survival and patient-reported health status.

Main Results:

  • 539 patients underwent 604 cardiac operations between 1972 and 2006.
  • 30-day mortality was 5.9% (2.7% after 2001); 10-year and 20-year survival rates were 84.7% and 71.2%, respectively.
  • Multivariate analysis identified predictors of mortality and survival, including hematocrit, valve repair/replacement, and preoperative rhythm.

Conclusions:

  • Cardiac surgery for Ebstein anomaly can be performed with low perioperative mortality.
  • Both tricuspid valve repair and replacement are associated with favorable long-term survival.
  • Factors such as ventricular dysfunction, elevated hematocrit, and outflow tract obstruction are associated with poorer outcomes.
Abstract

Related Concept Videos